We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Green Thumb Industries Inc. (GTBIF) Soars 11.3%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Green Thumb Industries Inc. (GTBIF - Free Report) shares ended the last trading session 11.3% higher at $12.88. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 15.9% loss over the past four weeks.
Green Thumb Industries Inc. recorded a strong price increase after news surfaced that U.S. Vice President Kamala Harris has urged the Drug Enforcement Administration to immediately reschedule cannabis to a lower-risk category, indicating the U.S. government’s latest attempt to back the move. Per Harris, marijuana being considered as dangerous as heroin and more dangerous than fentanyl is patently unfair.
This company is expected to post quarterly earnings of $0.05 per share in its upcoming report, which represents a year-over-year change of +25%. Revenues are expected to be $269.8 million, up 8.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Green Thumb Industries Inc., the consensus EPS estimate for the quarter has been revised 15.9% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on GTBIF going forward to see if this recent jump can turn into more strength down the road.
Green Thumb Industries Inc. belongs to the Zacks Medical - Products industry. Another stock from the same industry, Bio-Rad Laboratories (BIO - Free Report) , closed the last trading session 0.3% higher at $333.51. Over the past month, BIO has returned 1.1%.
For Bio-Rad, the consensus EPS estimate for the upcoming report has changed -22.6% over the past month to $2.09. This represents a change of -37.4% from what the company reported a year ago. Bio-Rad currently has a Zacks Rank of #4 (Sell).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Green Thumb Industries Inc. (GTBIF) Soars 11.3%: Is Further Upside Left in the Stock?
Green Thumb Industries Inc. (GTBIF - Free Report) shares ended the last trading session 11.3% higher at $12.88. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 15.9% loss over the past four weeks.
Green Thumb Industries Inc. recorded a strong price increase after news surfaced that U.S. Vice President Kamala Harris has urged the Drug Enforcement Administration to immediately reschedule cannabis to a lower-risk category, indicating the U.S. government’s latest attempt to back the move. Per Harris, marijuana being considered as dangerous as heroin and more dangerous than fentanyl is patently unfair.
This company is expected to post quarterly earnings of $0.05 per share in its upcoming report, which represents a year-over-year change of +25%. Revenues are expected to be $269.8 million, up 8.6% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Green Thumb Industries Inc., the consensus EPS estimate for the quarter has been revised 15.9% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on GTBIF going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Green Thumb Industries Inc. belongs to the Zacks Medical - Products industry. Another stock from the same industry, Bio-Rad Laboratories (BIO - Free Report) , closed the last trading session 0.3% higher at $333.51. Over the past month, BIO has returned 1.1%.
For Bio-Rad, the consensus EPS estimate for the upcoming report has changed -22.6% over the past month to $2.09. This represents a change of -37.4% from what the company reported a year ago. Bio-Rad currently has a Zacks Rank of #4 (Sell).